Cheryl Barton is director of PharmaVision, 

Articles

Novel mitophagy inducers and gene therapies that restore cellular function and decelerate the ageing process.

European Biotech Targeting Anti-ageing

 in 2014, Adam Goulder has over 30 years' experience within the maintenance engineering and asset management sectors including Pharmaceutical and Medical Devices manufacturing. As Head of Project Management and a Principal Consultant Adam oversees the management and implementation of enterprise asset management solutions to a wide range of organisations across the Pharmaceutical, Medical Devices, Healthcare, Logistics, Facilities Management, Utilities, Oil & Gas, and Transportation sectors. Adam is a Chartered Engineer, holds an MSc in Maintenance Engineering and Asset Management from the University of Manchester and is a member of the International Society of Pharmaceutical Engineers.

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

The bio/pharmaceutical industry is struggling with the challenge of staffing and training.

Training for Operational Excellence

Mike Hennessy Jr. is the President and CEO of 

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

Billions of Reasons to be Buoyant

Exploring the state of pharma patents following the Supreme Court’s Amgen v. Sanofi decision.

Unpacking Amgen v. Sanofi

Emma Palmer Foster is a Director at Discovery Park Ventures.

Start-ups are plagued with common issues that dramatically decrease their odds of achieving investor funding.

Perfecting the Pitch: Learning to Attract Investor Funding

If we view a change opposite of one’s interest as antithetical to innovation, we risk losing sight of our ultimate goal.

Innovation Idolatry

The debate surrounding drug pricing changes rages on.

Drug Pricing’s Static Changes

Podcasts

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Drug Solutions Podcast: Examining the State of Biopharma Investment

What factors do CDMOs consider vital to their success?

The Outsourcing Success Story 

COVID-19 has raised the specter of pandemic planning and the question of what can be done now to prevent future disaster.

Governance of  Future Pandemics

Context surrounding the Inflation Reduction Act is necessary for a comprehensive understanding of the global biopharma market.

The United States and the Global BioPharma Market

Feliza Mirasol is the science editor for 

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.



Ramping Up Nucleic Acid Therapy Development

The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.

Young Pups and Leopards

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

What can we take away from Pfifzer's acquisition of Seagen?

Zauberkugel: Pfizer’s Seagen Acquisition

Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely. 

Business Features